View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 21, 2011

Levomilnacipran Found Effective Against Major Depressive Disorder

Forest Laboratories and Pierre Fabre Medicament have presented the preliminary top-line results from a Phase III study of once-daily Levomilnacipran as a treatment for major depressive disorder in adults. Levomilnacipran (1S,2R-milnacipran) is a potent and selective inhibitor of the re

By cms admin

Forest Laboratories and Pierre Fabre Medicament have presented the preliminary top-line results from a Phase III study of once-daily Levomilnacipran as a treatment for major depressive disorder in adults.

Levomilnacipran (1S,2R-milnacipran) is a potent and selective inhibitor of the reuptake of norepinephrine and serotonin, which are known to regulate mood.

The randomised, double-blind, placebo-controlled and fixed-dose study, which involved 724 patients, showed a mean change from baseline to end of week eight in the Montgomery-Asberg Depression Rating Scale-Clinician Rated total score.

The study also demonstrated the safety and tolerability of Levomilnacipran in patients with major depressive disorder.

Results from two additional placebo-controlled Phase III studies are expected in 2011 and 2012.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology